Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Feb 2, 2021

ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field

Jan 12, 2021

ProMIS Neurosciences Announces Strategic Priorities for 2021

Nov 16, 2020

ProMIS Neurosciences Completes Offering of Special Warrants

Nov 11, 2020

ProMIS Neurosciences Announces Third Quarter 2020 Results

Nov 9, 2020

ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer’s disease

Nov 5, 2020

ProMIS Neurosciences Closes First Tranche of Private Placement

Oct 30, 2020

ProMIS Neurosciences’ Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research Symposium

Oct 29, 2020

ProMIS Neurosciences adds Dr. David Wishart to its Scientific Advisory Board

Oct 23, 2020

ProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of Special Warrants

Oct 21, 2020

ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab

  • arrow_back
  • 1…
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • …25
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy